Pharmacology for Nurses · Lower Respiratory Disorder Drugs

Xanthines, Leukotriene Modifiers, and Mast Cell Stabilizers

7 min read

On this page 9 sections

In 30 seconds
Why this matters
The college version
Eli explains
Worked example
Key takeaway
Check yourself
Study tools
Sources & references

In 30 seconds

Asthma and chronic obstructive pulmonary disease (COPD) are chronic airway diseases built on inflammation, bronchoconstriction, and excess mucus. The adrenergics and corticosteroids covered earlier in this chapter act broadly or rapidly; this topic adds three classes that interrupt specific steps in the airway's inflammatory cascade: xanthines, leukotriene modifiers, and mast cell stabilizers. What ties them together is their role: they are controller (preventive) therapies, not rescue therapies — they reduce the airway's tendency to narrow over time but do not stop an attack in progress. Knowing which step each class targets lets nurses predict why one controller is chosen over another, what to monitor, and how to teach correct use. All content is educational; verify drug selection, doses, schedules, and monitoring against current references, the formulary, and prescriber orders.

Why this matters

Patient safety: Each class carries distinctive risks — theophylline's narrow window, montelukast's neuropsychiatric warning, cromolyn's timing — and nurses often catch early warning signs.
Exam distinction: "Controller versus rescue" and "which mediator does each class block" are classic questions that separate memorization from understanding.
Adherence is a nursing issue: Controllers only work if taken regularly, even when the person feels well; teaching this is a core nursing responsibility.
Real-world impact: Asthma affects millions; reduces exacerbations, hospitalizations, and rescue-inhaler reliance.

The college version

Core Concepts

Controllers versus relievers

Asthma therapy organizes drugs by job. Relievers (short-acting inhaled bronchodilators) relax bronchial smooth muscle within minutes and treat breakthrough symptoms. Controllers are taken regularly — often daily — to prevent symptoms and exacerbations. All three classes in this topic are controllers. Mast cell stabilizers and leukotriene modifiers do not relieve an acute attack at all; theophylline has some bronchodilator effect, but it acts too slowly and carries too much risk to be a first-line reliever. A useful shortcut: controllers change the weather in the airways; relievers change the moment.

Xanthines: theophylline

Theophylline is the prototype , a chemical cousin of caffeine. Its mechanism is complex and still debated, but the important effects are nonselective inhibition (slowing cyclic AMP breakdown, which promotes bronchial smooth-muscle relaxation), adenosine receptor antagonism, and some anti-inflammatory activity. Two features shape its clinical reputation:

Narrow therapeutic window: The difference between a helpful and a toxic blood level is small, so therapy is guided by of serum concentrations. Early toxicity looks like caffeine overdose — nausea, tremor, insomnia, palpitations — and severe toxicity can progress to seizures or dangerous heart rhythms.
Many interactions: Theophylline is metabolized by CYP1A2. Smoking induces this enzyme (lowering theophylline levels), while certain other drugs inhibit it (raising levels and toxicity risk). Cimetidine and some antibiotics are classic interaction examples.

Because of these risks, theophylline is used less often today, but it still appears in practice and remains an exam staple.

Leukotriene modifiers

Leukotrienes are inflammatory lipid mediators released by mast cells and eosinophils during allergic and asthmatic responses. The cysteinyl leukotrienes (LTC₄, LTD₄, LTE₄) cause bronchoconstriction, mucus hypersecretion, mucosal edema, and eosinophil recruitment — chemical "fuel" for airway inflammation. Leukotriene modifiers attack this pathway at one of two points:

Receptor antagonists (montelukast, zafirlukast): block receptors, preventing the mediators from acting on airway tissue.
Synthesis inhibitor (zileuton): blocks the enzyme , reducing leukotriene production at the source.

These drugs are used for asthma prophylaxis, allergic rhinitis, and prevention of exercise-induced bronchoconstriction; they are taken regularly and do not stop an acute attack. Montelukast carries a regulatory warning about neuropsychiatric events — mood changes, agitation, sleep disturbances, and rarely suicidal thinking — so teach patients and families to report mood or behavior changes promptly.

Mast cell stabilizers

Cromolyn sodium (and the related nedocromil) works differently: it stabilizes mast cells, the immune cells whose degranulation releases histamine and other mediators that trigger bronchoconstriction. The critical teaching point is timing: cromolyn must be taken before exposure (exercise, anticipated allergens) and on a regular preventive schedule; it has no effect once an attack has started. Because inhaled cromolyn is barely absorbed systemically, it is generally well tolerated; the main nuisance is local cough or throat irritation.

Nursing considerations across the three classes

Verify before you give: Confirm the indication, device, and technique against current references, the formulary, and the prescriber's orders.
Teach the big idea: Controllers prevent — they are not for breakthrough symptoms — and stopping one abruptly can cause loss of control; any change is prescriber-directed.
Monitor class-specific red flags: theophylline — tremor, nausea, palpitations, and serum levels as ordered; leukotriene modifiers — mood and behavior changes; cromolyn — correct technique and timing.
Scope varies: Who may initiate, titrate, or teach these therapies depends on licensure and institutional policy.

Common Confusions

Do Not Confuse	With	Difference
Controller therapy	Rescue therapy	Controllers prevent attacks when taken regularly; rescue drugs relieve symptoms already present
Montelukast (receptor antagonist)	Zileuton (synthesis inhibitor)	One blocks leukotrienes from binding; the other blocks the enzyme that makes them
Mast cell stabilizers	Antihistamines	Stabilizers prevent mediator release; antihistamines block histamine after release — neither is an acute bronchodilator
Theophylline	Caffeine	Same chemical family, but theophylline is dosed and monitored as a medication with a narrow window
"Take before exercise" (cromolyn)	"Take when symptoms start" (rescue inhaler)	Timing is the whole point: prevent before exposure vs. relieve during an attack

Eli explains

The same idea, in plain words

Explain it like I’m 10

Think of the airway as a hallway that can swell shut during an asthma attack. These medicines are like fire-retardant paint: they make the hallway much less likely to swell, but they are not the extinguisher for a fire already roaring — that is the rescue inhaler. Theophylline calms the muscle in the walls, leukotriene modifiers block a chemical that pours fuel on the fire, and mast cell stabilizers stop the alarm cells from releasing that chemical at all.

Worked example

Mr. Chen, a person with persistent asthma, brings two new prescriptions: montelukast and cromolyn sodium. The student nurse reviews them with the instructor:

Identify each drug's job. Montelukast is a daily controller that blocks cysteinyl leukotriene receptors, reducing airway inflammation over time. Cromolyn is a preventive stabilizer used before triggers — Mr. Chen jogs daily, so it is scheduled before exercise.
Teach the difference. "Neither of these is for when you feel an attack coming — that's what your rescue inhaler is for. These work in the background to keep attacks from starting."
Anticipate monitoring. The student notes montelukast's mood/behavior warning and plans to ask at follow-up about sleep, mood, or energy changes; theophylline, if added later, would need serum levels and interaction screening.
Verify and document. The student checks both orders against the formulary and references, confirms inhaler technique, and documents teaching per policy.

This walkthrough shows the nursing pattern for all three classes: know the mechanism, teach the role (controller vs. rescue), monitor class-specific risks, and verify every order.

Key takeaways

Controllers ≠ rescue drugs. Mast cell stabilizers and leukotriene modifiers never treat an active attack; theophylline is not a first-line reliever.
Theophylline = narrow window + serum monitoring. Early toxicity mimics caffeine overdose; severe toxicity can cause seizures or dangerous rhythms.
CYP1A2 interactions: Smoking (inducer) lowers theophylline levels; inhibiting drugs raise them. Always screen the medication list.
Leukotriene pathway: Cysteinyl leukotrienes (LTC₄, LTD₄, LTE₄) cause bronchoconstriction, mucus, and edema. Receptor antagonists block the receptor; zileuton blocks 5-lipoxygenase.
Montelukast warning: Teach reporting of mood, behavior, or sleep changes — a real safety priority, not just a test fact.
Cromolyn timing: Must be taken before exposure; useless once bronchoconstriction begins.
Safety: Doses, schedules, and monitoring decisions come from current references, formulary, and prescriber orders — never from a study guide.

Check yourself

5 review questions from the chapter. Try each one, then open the answer.

A person asks whether their montelukast will help the wheezing they are having right now. What is the correct teaching?
Show answer
No — montelukast is a controller that prevents attacks over time; it will not stop current wheezing. The rescue inhaler is the right tool for breakthrough symptoms, and any change in the plan is prescriber-directed.
Why is therapeutic drug monitoring important for theophylline but not typically for cromolyn?
Show answer
Theophylline's therapeutic window is narrow — effective and toxic blood levels are close together — so serum levels guide dosing. Cromolyn is barely absorbed systemically, so toxicity is rarely the concern; timing and technique are.
Name the two places leukotriene modifiers can interrupt the leukotriene pathway, with an example drug class for each.
Show answer
Receptor antagonists (montelukast, zafirlukast) block cysteinyl leukotriene receptors; the synthesis inhibitor zileuton blocks 5-lipoxygenase.
What timing instruction is essential for mast cell stabilizers, and why?
Show answer
They must be taken before allergen or exercise exposure, because they prevent mast-cell degranulation; they cannot reverse bronchoconstriction once it has started.
Which adverse effect should patients taking montelukast be taught to report, and why is this emphasized?
Show answer
Mood, behavior, or sleep changes (neuropsychiatric events) — a rare but serious warning that warrants prompt reporting so the prescriber can reassess therapy.

Keep learning

Ready to build on this? Continue to the next lesson.

Study tools & related lessonsKey vocabulary · Related

Key vocabulary

Controller therapy: Medication taken regularly to prevent symptoms
Xanthine: Caffeine-related chemical class; theophylline is the prototype
Phosphodiesterase: Enzyme that breaks down cyclic AMP
Therapeutic drug monitoring: Measuring a drug's blood level to guide dosing
Cysteinyl leukotriene: Inflammatory mediator (LTC₄, LTD₄, LTE₄) causing bronchoconstriction and mucus
5-Lipoxygenase: Enzyme that synthesizes leukotrienes
Mast cell stabilizer: Drug that prevents mast cells from releasing inflammatory mediators (cromolyn)

Sources & references

openstax.org — Pharmacology

This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.

Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.